logo
  • About us
    • The Company in brief
    • Strategy
    • Market
    • Organisation
      • Management
      • Board of Directors
  • Our Drug Projects
    • Science
    • Pipeline
    • Our ongoing study
    • Disorders
      • Primary Biliary Cholangitis (PBC)
      • Hepatic Encephalopathy (HE)
      • Potential expansion
  • Our ongoing study
  • Investors
    • Financial Reports
    • Corporate Governance
    • General meetings
    • Calendar
    • Press Releases
  • Media
    • Press Releases
    • Presentations and posters
    • Subscribe
  • Contact

Extra General Meeting, August 2022

August 10, 2022

An extraordinary general meeting was held on Wednesday 10 August 2022.

Documents

  • Notice to attend EGM 2022
    July 5, 2022 English
  • Kallelse till extra bolagsstämma 2022
    July 5, 2022 Svenska
  • Postal voting form (EGM)
    July 5, 2022 English
  • Formulär för poströstning (EGM)
    July 5, 2022 Svenska
  • Power of attorney form (EGM)
    July 5, 2022 English
  • Fullmaktsformulär (EGM)
    July 5, 2022 Svenska
  • Investors
    • Financial Reports
    • Corporate Governance
    • General meetings
    • Calendar
    • Press Releases

CONTACT

Viktor Drvota
CEO and Chairman of the Board
Phone +46 8-524 860 70
[email protected]

All contacts

VISITING ADDRESS

Umecrine Cognition AB
Karolinska Institutet Science Park
Nanna Svartz väg 6A,
171 65 Solna
Sweden

COMPANY INFORMATION

Umecrine Cognition AB
Registered office in Umeå
Reg no 556698-3655

  • Cookies
  • Privacy Policy